TABLE II.
Tumour type | Indication | Chemotherapy agent or agents | Benefit |
---|---|---|---|
Head and neck | Locally advanced disease | Cisplatin, 5fu, cetuximab | Improved organ preservation and survival |
nsclc | Stage iiib, nonmetastatic inoperable disease | Cisplatin, carboplatin, etoposide, paclitaxel | Curative in poor surgical candidates |
sclc | Limited stage disease | Cisplatin, etoposide | Curative in approximately 20% |
Esophageal | Locally advanced | Cisplatin, 5fu | Increase cure rate, survival, and organ preservation |
Glioblastoma | Adjuvant | Temozolomide | Survival benefit |
5fu = 5-fluorouracil; nsclc = non-small-cell lung cancer; sclc = small-cell lung cancer.